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ABSTRACT
Prokaryotes encode various host defense systems
that provide protection against mobile genetic ele-
ments. Restriction–modification (R–M) and CRISPR–
Cas systems mediate host defense by sequence
specific targeting of invasive DNA. T-even bacte-
riophages employ covalent modifications of nucle-
obases to avoid binding and therefore cleavage of
their DNA by restriction endonucleases. Here, we
describe that DNA glucosylation of bacteriophage
genomes affects interference of some but not all
CRISPR–Cas systems. We show that glucosyl modi-
fication of 5-hydroxymethylated cytosines in the DNA
of bacteriophage T4 interferes with type I-E and type
II-A CRISPR–Cas systems by lowering the affinity of
the Cascade and Cas9–crRNA complexes for their
target DNA. On the contrary, the type V-A nuclease
Cas12a (also known as Cpf1) is not impaired in bind-
ing and cleavage of glucosylated target DNA, likely
due to a more open structural architecture of the
protein. Our results suggest that CRISPR–Cas sys-
tems have contributed to the selective pressure on
phages to develop more generic solutions to escape
sequence specific host defense systems.
INTRODUCTION
In many environments, bacteria are subject to strong selec-
tive pressure by bacteriophages (phages). The number of
phages exceeds that of their hosts in most ecosystems, out-
numbering them up to 150-fold (1). In response to this se-
lective pressure, bacteria have developed a diverse palette of
defense mechanisms including prevention of phage adsorp-
tion, blocking of DNA entry, restriction of phage DNA,
and abortive infection mechanisms (2,3). Two of these
defense mechanisms, restriction–modification (R–M) and
Clustered Regularly Interspaced Short Palindromic Repeat
(CRISPR)-CRISPR-associated (Cas) systems, act on the
DNA level by selectively degrading invading DNA. Dis-
tinction between native and foreign DNA by R–M sys-
tems is often based on chemical modification (e.g. methy-
lation) of adenines and cytosines in host genomic DNA,
which protects host DNA from cleavage by specific restric-
tion endonucleases. Escherichia coli K-12 harbors the type
I restriction enzyme EcoK encoded by the hsdR gene that
cleaves unmethylated DNA at 5′-AAC(N6)GTGC and 5′-
GCAC(N6)GTT sequences and three type IVR–M systems
encoded by McrA, McrBC and mrr that cleave methylated
DNA (4,5). Together, these R–M systems limit horizontal
gene transfer.
Recognition of invading DNA by type I, II and V
CRISPR–Cas systems is based on base pairing of the in-
vader DNAwith CRISPRRNAs (crRNAs). These host en-
coded crRNAs guide effector complexes to complementary
target DNA (also called protospacer) which is subsequently
cleaved by the effector complex or by recruited nucleases
(6,7). Even though all different types of CRISPR–Cas sys-
tems have a common role in immunity, they are struc-
turally and mechanistically diverse. Based on this diversity,
CRISPR systems are divided into two different classes and
six different types (8,9). Type I CRISPR systems are the
most abundant CRISPR type in nature (6), and comprise
a multiprotein crRNA–effector complex (named Cascade)
and a nuclease (Cas3) to bind target DNA. After target
DNA recognition, Cascade recruits Cas3 that mediates tar-
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Figure 1. Modifications of nucleobases in phage T4 DNA. (A) Cytosine
present in phage T4(C). (B) 5-Hydroxymethylation of cytosine present
in phage T4(hmC). (C) Glucosyl-5-hydroxymethylation present in phage
T4(ghmC).
get DNA degradation (10,11). The best characterized ex-
ample of type II CRISPR–Cas systems is the Cas9 nucle-
ase, a single effector protein which facilitates both crRNA-
mediated DNA binding and DNA cleavage (8). Recently,
type V-A CRISPR systems were discovered (12). Like type
II systems, type V-A systems employ a single effector en-
zyme named Cas12a, which provides an interesting alterna-
tive to Cas9 in genome editing (12,13).
In response to the selective pressure posed by anti-viral
defense systems in bacteria, phages have evolved several
mechanisms to escape anti-viral defense systems. Phages
can evade sequence-specific host defense systems by mutat-
ing target sequences (14–16). While this allows for efficient
escape from restriction endonucleases, mutations in DNA
sequences targeted by CRISPR–Cas systems can trigger a
process called priming, which leads to an accelerated up-
date of the CRISPR memory repertoire (17). Furthermore,
phages may use recombination of their genomes to get rid
of CRISPR target sites (18,19). In addition to mutation and
recombination of DNA, phages can escape R–M systems
by expressing inhibitory proteins. Such proteins can inhibit
R–M immunity by degradation of R–M cofactors, masking
of restriction sites, or modification of phage DNA (2). Ad-
ditional strategies include DNA mimicry, as exemplified by
the Ocr protein of phage T7 that mimics DNA to sequester
EcoKI (20,21). Recently, phage-encoded proteins that in-
hibit CRISPR–Cas systems have been characterized (22–
24). Inhibition of CRISPR–Cas systems by anti-CRISPR
(ACR) proteins occurs via distinct mechanisms. Two Acr
proteins (AcrF1 and AcrF2) were found to bind the type
I-F Csy complex, inhibiting the binding of target DNA,
while another Acr protein (AcrF3) binds to Cas3, block-
ing its interaction with Cascade to inhibit target degrada-
tion (25). Three recently identified families of ACRs are
encoded by mobile elements in bacteria and are shown to
inhibit Neisseria meningitidis Cas9 by direct binding (26).
ACR proteins AcrIIA1-4 encoded by Listeria monocyto-
genes prophages prevent Cas9 binding and can be used to
regulate the genome engineering activity of Streptococcus
pyogenesCas9 (27). ACRproteins that inhibit SpyCas9 have
also been found in virulent bacteriophages (28).
Another way to escape host defense is found in T-even
phages that infect E. coli (29). Phage T4 has evolved a path-
way to bypass the R–M systems of E. coli by substitution
of its genomic cytosines with 5-hydroxymethylcytosines (5-
hmC) (Figure 1A and B). The dNTP synthesis complex
(DSC) which comprises both host- and phage-encoded
enzymes performs this substitution before DNA synthe-
sis (30). Degradation of the host genome by T4-derived
DenA and DenB nucleases provides an increased pool of
dCTP, which is converted to dCMP by the phage-encoded
dCTPase gp56. Subsequently, dCMP is converted into
5-hydroxymethyl-dCMP (5-hmdCMP) by phage-encoded
Deoxycytidylate 5-hydroxymethyltransferase gp42 (31).
Conversion of 5-hmdCMP to 5-hmdCDP is then catalyzed
by the phage-encoded dNMPkinase gp1.Host-encoded nu-
cleoside diphosphate kinase Ndk catalyzes the final con-
version to 5-hmdCTP, which is incorporated by T4 DNA
polymerase into the DNA as 5-hmC. To avoid immu-
nity escape by 5-hmC modification, E. coli encodes the
McrBC system, which specifically degrades 5-hmC mod-
ified DNA (32). However, T4 is impervious to this mod-
ification dependent system because 5-hmC residues are
further modified with glucose moieties derived from uri-
dine diphosphate glucose (UPDG). These are covalently at-
tached to the 5-hydroxyl group of 5-hmC by phage-encoded
alpha- and beta-glucosyl transferases, yielding glucosyl-
5-hydroxymethylcytosine (5-ghmC) (33) (Figure 1C). As
DNA glucosyl-5-hydroxymethylation provides an effective
way to escape immunity by most R–M systems, the ques-
tion arises whether it also protects against certain types of
CRISPR–Cas immunity, and what themechanistic basis for
protection from CRISPR interference would be.
We have tested the effect of DNA glucosylation on the
activity of type I-E, type II-A and type V-A CRISPR–Cas
systems.We demonstrate that T4with 5-ghmCDNAcan es-
cape type I-E and II-A interference by reducing target bind-
ing affinity of Cascade and Cas9, respectively. Interestingly,
5-ghmC modifications do not lower target binding affin-
ity and cleavage efficiency of the type V-A effector nuclease
Cas12a. The structural basis for the observed differences as
well as potential applications for the described results are
discussed.
MATERIALS AND METHODS
Bacterial strains and plasmid construction
Cells were made chemically competent using the RuCl
method and transformed by applying a heat-shock as de-
scribed in theQIA expressionist handbook (QIAGEN). For
the experiments with Type I-E CRISPR–Cas, E. coli T7 Ex-
press (NEB) was transformed with pWUR400, pWUR797
and pWUR800, pWUR801 or pWUR802 (Supplementary
Table S1) and used for plaque assays with phage T4. For the
in vivo experiments with Type II-A CRISPR–Cas,E. coliT7
Express was transformed with pWUR805 and pWUR806,
pWUR809 or pWUR810 (Supplementary Table S1).
Bacteriophage strains and propagation
Phage T4(ghmC) (CBS-KNAW Biodiversity Centre,
Utrecht, Netherlands) was propagated in E. coli B834
(Su−). Phage T4(C) (dCTPase−, denA, denB, alc−) was
kindly provided by Prof. Elisabeth Kutter (Evergreen State
College) and propagated in E. coli B834 or CR63 (Su+).
T4(hmC) (-, -glucosyltransferase) was kindly provided
by Peter Weigele (NEB, Ipswich) and propagated in E.
coli T7 Express (mcrC-mrr). The phage T4(C) mutant
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we used in our analysis was a quintuple mutant of genes
alc, denB, denA and dCTPase. Genes denA and denB
encode endonuclease II and IV respectively and denA and
denB mutations allow the phage to contain C DNA. The
alc mutation allows for the production of late proteins,
enabling bursts of phage.
Plaque assays and efficiency of plating calculation
Escherichia coli strains were grown at 37◦C in Luria Broth
(LB; 5 g/l yeast extract, 10 g/l tryptone, 5 g/l NaCl) at 180
rpm or on LB-agar plates containing 1.5% (w/vol) agar.
When required, mediumwas supplemented with the follow-
ing: ampicillin (Amp; 100 g/l), chloramphenicol (Cam; 25
g/ml), kanamycin (Kan; 50 g/ml) or streptomycin (Str;
50g/ml). Bacterial growthwas assessed spectrophotomet-
rically at 600 nm (OD600). To induce cas gene expression,
IPTG (isopropyl -D-1 thiogalactopyranoside) was added
to the final concentration of 1 mM when the bacterial cul-
ture reached and OD600 of approximately 0.4. After 30 min
of Cas protein and crRNA production, the cells were used
in double agar layer plaque assays with phage T4(ghmC),
T4(hmC), and T4(C). Plaque assays were performed in trip-
licate. The sensitivity of the host to phage infection was cal-
culated as the efficiency of plaquing, which is the plaque
count ratio of a strain containing an anti-T4 CRISPR, to
that of a strain containing a CRISPR with non-targeting
spacers. Anti-T4 spacers were designed by picking a PAM-
flanked protospacer in two essential T4 genes (gene 19 and
gene 22). CRISPR protospacer sequences are provided in
Supplementary Table S2. A two tailed t-test was performed
to calculate whether the differences were significant.
The presence or absence of modifications of T4 DNA
was verified by analysis using restriction enzymes. Isolated
DNA was incubated with enzymes that are either sensitive
or not sensitive to 5-hmC or 5-ghmC. Our analysis con-
firmed that our T4 stock contains 5-ghmC DNA and our
T4(C) stock contains C DNA. The presence of 5-hmC in
phage T4(hmC) was verified by plating on E. coli express-
ing theMcrBC restriction enzyme, which is active on 5-hmC
DNA but not on 5-ghmC DNA. Inability of T4(hmC) to
propagate reveals the presence of 5-hmC DNA.
Design and synthesis of modified dsDNA
All in vitro assays were done using a 98 bp dsDNA target
containing the spacer 8 (sp8) sequence (Supplementary Ta-
ble S2). The target was amplified using the primers BG8415
& BG8416 (Supplementary Table S2). PCR products were
generated using both Q5 high-fidelity DNA polymerase
and TaqDNApolymerase (NEB). hm5-dCTP (Bioline) was
used in the PCR reactions to obtain hydroxymethylated tar-
gets. PCR conditions were optimised for each of the modi-
fied dNTPs used. Typical PCR conditions were as follows:
50 l PCR reactions with final concentrations dNTPs 200
M, primers 0.5 M, DNA template 100 ng, 1.25 U Taq
polymerase. The following parameters were used: denatu-
ration at 95◦C for 30 s followed by 30 cycles of 95◦C for 30
s, 46◦C for 60 s, 68◦C for 60 s with a final extension at 68◦C
for 3 min. For Q5 DNA polymerase (1 U) the following pa-
rameters were used; 98◦C 30 s denaturation, followed by 30
cycles at 98◦C for 30 s 61◦C for 30 s, 72◦C for 20 s with a final
extension at 72◦C for 2 min. The PCR products were sub-
sequently purified by QIAprep Spin Miniprep Kit (Qiagen)
following the manufacturer’s instructions. Purified samples
were quantified using a NanoDrop 2000C (Thermo Scien-
tific) and analyzed by native PAGE.
Three different spacers were designed for the target se-
quence for Type I-E, Type II-A and Type V CRISPR sys-
tems. Each of these spacers was designed to have a suitable
PAM for the respective CRISPR Type (34). The designed
spacers can be found in Supplementary Table S2.
Enzymatic glucosylation of the purified 5-hmC dsDNA
was used to synthesize DNA with glucosylated 5-hmC.
T4 Phage -glucosyltransferase (NEB) 1 U was incubated
with approximately 1 g of 5-hmC dsDNA, 40 M UDP-
glucose at 37◦C for 16 h. The DNA products were subse-
quently purified usingQIAprep SpinMiniprepKit (Qiagen)
and analysed by native PAGE.
DNA targets containing 5-hmC modifications in the
PAM region were produced by annealing oligonucleotides
BG6508–6510 to BG6506. Oligonucleotides BG6508–6510,
containing 5-hydroxymethyldeoxycytidine, were purchased
from Integrated DNA Technologies (IDT).
Target DNA was subsequently glucosylated as described
above.
Radiolabeling of target DNA
TargetDNA containing unmodified cytosine, 5-hmC and 5-
ghmCwere 5′ radioactively labeled using T4 Polynucleotide
Kinase (PNK) (NEB). Conditions are 1× PNK reaction
buffer (NEB), 50 pmol [ -32P] ATP (Perkin Elmer) and 25
pmol target DNA in a 50 l reaction. The reaction was car-
ried out at 37◦C for 30 min and subsequently inactivated at
65◦C for 20 min.
Preparation of crRNA and sgRNA
The Cas9 sgRNA was made by in vitro transcription (IVT)
of partly overlapping primers. DNA oligonucleotides (oli-
gos) used for IVT were PAGE purified (Supplementary Ta-
ble S3). IVT was performed using the HiScribe™ T7 Quick
High Yield RNA Synthesis Kit (NEB) in 30 l containing
10 l NTP buffer mix, 1 g DNA and 2 l T7 polymerase.
The reaction was incubated for 4 h at 37◦C, thereafter 20
l Milli-Q and 2 units DNase I (NEB) were added to re-
move target DNA for 15 min at 37◦C. 10 l 6× loading dye
(Thermo Scientific) was added to both samples for separa-
tion and isolation from a denaturing PAGE gel. The sam-
ples were heated for 5min at 95◦C and loaded on a 7Murea
8% PAGE gel, together with a Low Range ssRNA Ladder
(NEB). The gel was run for 3 h at 15 mA in 1× TBE. Af-
ter 3 h, the gel was stained using 1× SYBR gold (Thermo
Scientific) in 1× TBE for 10 min. For both RNA oligos, the
band at 103 nt was cut from gel.
The gel fragments were ground using a pipet tip. 1 ml of
RNA elution buffer (0.5 M NaAc, 10 mM MgCl2, 1 mM
EDTA, 0.1%SDS)was added and incubated for 2 h at 37◦C.
The sample was transferred to a gel extraction column (Zy-
moclean) and centrifuged at 13 200× g for 1 min. The flow-
through was purified on a Microcon 30 column (Millipore)
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by centrifugation at 16 000 × g for 20 min at 4◦C. RNA
was washed twice using 500 l Milli-Q and centrifuged at
16 000 × g for 20 min at 4◦C. RNA was resuspended on a
filter column in 50 l Milli-Q, and retrieved by centrifuging
the column upside down for 5 min at 6000 × g. RNA quan-
tity and quality were analysed using NanoDrop and Dena-
turing PAGE. The 48 nt crRNA and non-complimentary
crRNA for Cas12a assays were synthesized RNA Oligos
(Sigma, Supplementary Table S3).
Cascade and Cas3 degradation reactions
Cascade purification was performed as described in (10).
Cas3 was purified as described in (35). Target DNA con-
structs were incubated with 100 M Cascade and 10 M
Cas3 in reaction buffer (10 mM HEPES pH 7.5, 60 mM
KCl, 50MCoCl2, 10 mMMgCl2 and 2mMATP) at 37◦C
for 2 h. Reactions were stopped by transferring the tubes
to ice and addition of 4 l 6× loading dye (Thermo Scien-
tific). Reaction products were run on a 6% acrylamide gel
(with 7 M urea and 1× TBE). The gel was run in 1× TBE
for ∼4 h at 15 mA and subsequently exposed for 48 hours
in a phosphor imaging cassette (Molecular Dynamics) at –
20◦C. The phosphor imaging cassette was scanned using a
Personal Molecular Imager (Bio-Rad).
Cas9 cleavage reactions
For Cas9 Cleavage reactions 33 nM Cas9 (NEB), 120 nM
sgRNA and 1× Cas9 buffer (NEB) were pre-incubated for
20 min at 37◦C. Subsequently 5′ 32P-radiolabeled target
DNAwas added to a final concentration of 3 nMand the re-
action was incubated for 2 h at 37◦C. 30 l 2× formamide
loading dye (95% formamide, 0.125% bromophenol blue)
was added and the complete samples were heated to 95◦C
for 5 min and loaded on an 8% acrylamide gel (with 7 M
urea and 1× TBE). The gel was run in 1× TBE for ∼4 h
at 15 mA and subsequently exposed for 16–48 h in a phos-
phor imaging cassette (Molecular Dynamics) at –20◦C. The
phosphor imaging cassette was scanned using a Personal
Molecular Imager (Bio-Rad).
Cas12a protein purification
A codon optimized Cas12a gene was cloned into a bac-
terial expression vector [6-His-TEV-Cas12a, a pET-based
vector that was a gift from Scott Gradia (Addgene plas-
mid # 29653)]. One liter of LB growth media with 100
g/ml ampicillin was inoculated with 10 ml overnight cul-
ture Rosetta (DE3) (EMD Millipore) cells containing the
Cas12a expression construct. Growth media plus inoculant
was grown at 37◦C until the cell density reached 0.5 OD600,
then the temperature was decreased to 20◦C. Growth was
continued until OD600 reached 0.6 when a final concentra-
tion of 500 M IPTG was added to induce Cas12a expres-
sion. Expression took place for 14–18 h before harvesting
cells and freezing them at –20◦C until purification.
Cell paste was suspended in 20ml of Lysis Buffer (50mM
NaH2PO4 pH 8, 500 mMNaCl, 1 mM 2-mercaptoethanol,
10 mM imidazole) supplemented with protease inhibitors
(Roche complete, EDTA-free) and lysozyme. Once homog-
enized, cells were lysed by sonication (Bandelin Sonoplus)
and then centrifuged at 16 000 × g for 1 h at 4◦C to clear
the lysate. The lysate was filtered through 0.22 m filters
(Mdi membrane technologies) and applied to a nickel col-
umn (HisTrapHP, GE lifesciences), washed and then eluted
with 250 mM imidazole. Fractions containing protein of
the expected size were pooled and dialyzed overnight into
the dialysis buffer (250 mM KCl, 20 mM HEPES/KOH,
1 mM DTT). After dialysis, sample was diluted 1:1 in 10
mM HEPES/KOH pH 8, and loaded on a heparin FF col-
umn pre-equilibrated in IEX-A buffer (150 mM KCl, 20
mM HEPES/KOH pH 8). Column was washed with IEX-
A and then eluted with a gradient of IEX-C (2 M KCl, 20
mMHEPES/KOH pH 8). The sample was concentrated to
700 l prior to loading on a gel filtration column (HiLoad
16/600 Superdex 200) via FPLC (AKTA Pure). Fractions
from gel filtration were analyzed by SDS-PAGE; fractions
containing Cas12a were pooled and concentrated to 200 l
(50 mM Tris–HCl pH 8, 2 mM DTT, 5% glycerol, 500 mM
NaCl) and either used directly for biochemical assays or
frozen at –80◦C for storage.
Cas12a cleavage reactions
Cleavage assays were done by pre-incubating 100 nM
Cas12a with 400 nM crRNA in 1× Cas9 buffer (NEB) for
20 min at 37◦C. Thereafter 8 nM 5′ 32P radiolabeled tar-
get DNA was added in a 30 l reaction and incubation was
done at 37◦C for 2 h. 30 l 2× formamide loading dye was
added and the complete samples were heated to 95◦C for
5 min and loaded on an 8% acrylamide gel (with 7 M urea
and 1×TBE). The gel was run in 1×TBE for∼4 h at 15mA
and subsequently exposed for 16–48 h in a phosphor imag-
ing cassette (Molecular Dynamics) at –20◦C. The phosphor
imaging cassette was scanned using a Personal Molecular
Imager (Biorad).
Cascade electrophoretic mobility shift assays
Cascade electrophoretic mobility shift assays were per-
formed based on (36). Incubation reactions were performed
with Cascade–crRNA (sp8) complex concentrations of 0,
1, 3, 10, 30, 100, 300 and 1000 nM. Dilutions of the Cas-
cade stock solution (2.78 mg/ml) were made in equilibra-
tion buffer (20 mM HEPES pH 7.5, 75 mM NaCl, 1 mM
DTT). 3 nM 5′ 32P radiolabeled target was incubated with
Cascade complex in 1× Equilibration buffer in a 30 l re-
action. The reaction was incubated for 30 min at 37◦C. 6
l 6× loading dye (Thermo Scientific) was added and the
complete samples were loaded on a native 8% acrylamide
gel containing 1× TBE. The gel was run at 15 mA for 2–3
h, after which the gel was placed in a phosphor imaging cas-
sette and stored for 16–48 h at –20◦C. The phosphor imag-
ing cassette was scanned using a PersonalMolecular Imager
(Bio-Rad).
dCas9 and dCas12a electrophoretic mobility shift assays
Electrophoretic mobility shift assays with Cas9 and Cas12a
were done using catalytically dead versions of the proteins,
dCas9 and dCas12a (12,37). 1MdCas9 and dCas12awere
incubated with 4 M sgRNA and crRNA respectively in
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Figure 2. Efficiency of plaquing (EOP) assays of T4 phages on E. coli cells expressing CRISPR–Cas systems targeting T4 genes 19 or 22. (A) Represen-
tation of the circular genome of bacteriophage T4. Positions of protospacer sequences and PAMs are shown (indicated by orange bars and purple bars
respectively). Glucosyl-5-hydroxymethylcytosines are indicated in red and nucleotides that base pair with crRNA are indicated by black dots. (B) EOP
of T4 phages on E. coli cells expressing targeting Cascade complexes normalized to EOP on non-targeting strains. (C) EOP of T4 phages on E. coli cells
expressing targeting Cas9 proteins normalized to EOP on non-targeting strains.
binding buffer (20 mM HEPES, pH 7.5, 250 mM KCl, 2
mM MgCl2, 0.01% Triton X-100, 0.1 mg/ml bovine serum
albumin, 10% glycerol) for 10 min at 25◦C as described in
(38). A dilution series was made with 0.1, 0.3, 1, 3, 10, 30,
100 and 300 nM final protein concentration using binding
buffer. 3 nM 5′ 32P-radiolabeled target DNA was added in
a 30 l reaction and incubated for 10 minutes at 37◦C. 10
l 6× loading dye (Thermo Scientific) was added and the
complete samples were loaded on a 12% native acrylamide
gel containing 1× TBE. The gel was run in 1× TBE at 15
mA for 2–3 h. Subsequently, the gel was exposed for 16–48
h in a phosphor imaging cassette (Molecular Dynamics) at
–20◦C. The phosphor imaging cassette was scanned using a
Personal Molecular Imager (Biorad)
Structural Modeling of modified target DNA binding to Cas-
cade, Cas9 and Cas12a
Structural coordinates of glucosyl-5-hydroxymethyl mod-
ified thymine was isolated from an existing model (PDB
308D; (39)). The modified nucleotide was statically mod-
elled onto target strand (TS) and non-target strand (NTS)
nucleotides in structures of E. coli Cascade (PDB: 5H9F;
(40)), S. pyogenes Cas9 (PDB: 5F9R; (41)), and F. novi-
cida Cas12a (PDB: 5NFV; (42)) in WinCoot 0.8.3 using
Least Squares Fit Superpose. Clashes between the DNA
modifications and the polypeptide chain were identified us-
ing the MolProbity (43) output of the Comprehensive Val-
idation Tool within Phenix (44). Identified clashes between
the glucosyl-5-hydroxymethyl modification and polypep-
tide residues are schematically indicated in Figure 7.
RESULTS
Phages escape CRISPR–Cas interference by DNA glucosy-
lation
The majority of phages that contain 5-ghmC modifications
in their DNA infect gammaproteobacteria (45). Hence,
anti-viral defense systems that are effective against 5-ghmC
DNA-containing phages may be expected among this class
of bacteria. To this end we assessed the ability of the na-
tive type I-E CRISPR–Cas system of the gammaproteobac-
terium E. coli to provide resistance against phage T4. Two
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Figure 3. Effect of T4 DNA modifications on type I-E CRISPR–Cas sgRNA mediated DNA targeting. (A) Schematic of DNA targeting and R-loop
formation by Cascade. Modified cytosine residues are indicated in red. (B) Cleavage assay of Cas3 in conjunction with Cascade on 98 bp modified targets,
indicated by black arrow. The marker is indicated by white arrows. Cascade effector complexes are loaded with either targeting crRNA (T crRNA) or
non-targeting crRNA (NT crRNA). Restriction products of Cas3 are of undefined length. (C). Electrophoretic Mobility Shift Assay (EMSA) of Cascade
on target DNA containing C, 5-hmC or 5-ghmC (indicated by black arrow) at increasing protein concentrations [nM]. Fraction of bound target is indicated
by white arrows, dotted lines represent separate gels.
plasmids expressing crRNAs against essential T4 genes
were constructed (Supplementary Table S2). The crRNAs
target T4 gene 19 (crRNA19), encoding a tail tube pro-
tein, and T4 gene 22 (crRNA22), encoding the prohead
core protein. Escherichia coli cells expressing Cascade and
Cas3 were transformed with the plasmid encoding the cr-
RNAs and were subsequently tested for their sensitivity
to infection by a panel of T4 phages. Phage T4(C) con-
tains unmodified cytosine, T4(hmC) contains 5-hmC, and
T4(ghmC) contains 5-ghmC. Infectivity of the phages was
normalized against E. coli cells containing a CRISPR ar-
ray harboring a non-targeting spacer (Figure 2). Efficiency
of plaquing (EOP) by T4(C) was reduced 104-fold by cells
expressing targeting Cascade as compared to cells express-
ing non-targeting Cascade. Similarly, EOP by T4(hmC) was
reduced 105-fold by cells expressing targeting Cascade. In
contrast, EOP by T4(ghmC) was lowered only 10-fold by
cells expressing targeting Cascade. We therefore conclude
that CRISPR–Cas type I-E resistance is severely inhibited
by 5-ghmC modifications, but not by 5-hmC modifications
of phage DNA.
Next, we tested whether the type II-A CRISPR–Cas sys-
tem of Streptococcus pyogenes mediates immunity against
T4 phages in E. coli. E. coli cells expressing Cas9 and
tracrRNA were transformed with plasmids encoding cr-
RNAs targeting T4 genes 19 and 22 and subsequently tested
for sensitivity to infection by phages T4(C), T4(hmC),
and T4(ghmC) (Figure 2B). Efficiency of plaquing (EOP)
by T4(C) and T4(hmC) is decreased 104-fold in cells ex-
pressing targeting Cas9 compared to non-targeting Cas9.
Although both chosen crRNAs mediated efficient target-
ing of T4(hmC), crRNA19 provided lower resistance than
crRNA22, indicating spacer-specific interference efficien-
cies on normal DNA. In contrast to EOP of T4(C) and
T4(hmC), EOP of T4(ghmC) is similar between cells ex-
pressing targeting or non-targeting Cas9. We therefore con-
clude that, like type I-E systems, type II-A CRISPR–Cas
systems are severely impaired by phageDNAglucosylation.
Escaping phages carry seed mutations
We noticed that each of the three T4 phages generated
plaques on CRISPR targeting strains, indicating that these
phages escaped CRISPR–Cas immunity. To determine the
nature of this escape, we sequenced the target site of the dif-
ferent plaque-forming T4 phages (Tables S4 and S5). The
majority (23/34) of T4(C) and T4(hmC) phages that es-
caped from type I-E or type II-A immunity contained a
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Figure 4. Effect of T4DNAmodifications on type II-ACRISPR–Cas sgRNAmediatedDNA targeting. (A) Schematic ofDNA targeting byCas9.Modified
cytosine residues are indicated in red. Cleavage sites are indicated by black arrows. (B) Cleavage assay of Cas9 on 98 bp modified targets (indicated by
black arrow). Cas9 is loaded with either targeting sgRNA (T sgRNA) or non-targeting sgRNA (NT sgRNA). Restriction products of Cas9 are 61 and 37
bp. (C) EMSA of dCas9 on target DNA containing C, 5-hmC or 5-ghmC (indicated by black arrow) at increasing protein concentrations [nM]. Fraction
of bound target is indicated by white arrows.
single mutation in the target sequences. Almost all muta-
tions (20/23) were located in the seed region of the target
sequences. This is a region in the target site that is highly
intolerant for mismatches during CRISPRmediated immu-
nity (46). Surprisingly, for both systems none of the muta-
tions were located in the PAM (Protospacer adjacent mo-
tif). The PAM is a short motif adjacent to the DNA target
sequence (PAM) important for efficient target recognition
and avoidance of self-targeting, and is commonly prone to
accumulating escape mutations.
Thus, several target DNA sequences in T4(C) and
T4(hmC) phages escaping type I-E or II-A systems did not
contain mutations. To ensure these phages were not rever-
tants in which the T4(ghmC) genotype was restored, the
dCTPase gene of the escape mutants was PCR amplified
and sequenced. This confirmed that the T4(C) phages still
had the dCTPase deficient genotype, which prevents in-
corporation of 5-ghmC, and suggests the mutants escaped
CRISPR immunity in another way (47). In contrast to
T4(C) and T4(hmC) phages that successfully infected E.
coli, none of the T4(ghmC) phages infecting E. coli express-
ing type I-E and type II-A systems had mutations in the
DNA targeted by the CRISPR systems. Sequencing of es-
cape mutant phages shows that T4(C) and T4(hmC) phages
mostly escape CRISPR immunity bymutating the target se-
quence. In contrast, T4(ghmC) infection does not require
mutation of DNA for efficient infection. This indicates that
the 5-ghmC modification itself allows efficient escape from
type I-E and type II-A CRISPR–Cas systems
DNA glucosylation inhibits Cascade target binding
To understand the molecular basis for escape from
CRISPR–Cas immunity, we reconstituted CRISPR inter-
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Figure 5. Effect of T4 DNA modifications of PAM-complementary cy-
tosines on type II-A CRISPR–Cas sgRNA mediated DNA targeting.
Cleavage assay of Cas9 on target DNA containing 5-hmC (indicated in
red). Cas9 is loaded with either targeting sgRNA (T sgRNA) or non-
targeting sgRNA (NT sgRNA). Restriction products of Cas9 are 57 and
33 bp. The marker is indicated by white arrows.
ference with type I-E components in vitro (Figure 3A). Af-
ter pre-incubation of crRNA-bound Cascade with unmod-
ified, 5-hmC, or 5-ghmC target DNA, the capacity of Cas3
to degrade these targets was assessed. Cas3, in conjunc-
tion with Cascade, was able to degrade 5-hmC DNA and
the unmethylated control DNA, but no degradation of 5-
ghmC target DNAwas observed (Figure 3B). To determine
whether this was due to inhibition of Cas3 or rather due to
inhibition of target binding by Cascade, we performed elec-
trophoretic mobility shift assays (EMSAs) with Cascade
(Figure 3C). The EMSAs showed that sequence-specific
binding of targets containing 5-hmC is consistently reduced
compared to targets containing unmodified cytosines. In
addition, we were unable to observe binding of 5-ghmC
targets, indicating that phages with glucosylated DNA es-
cape from type I-E CRISPR immunity by preventing bind-
ing of Cascade to the target DNA. Even though reduced
binding affinity of Cascade to targets containing 5-ghmC is
reduced, thereby allowing escape from CRISPR–Cas inter-
ference, inability of Cas3 to cleave glucosylated DNA can-
not be excluded even when stable binding of target DNA by
Cascade would occur.
Glucosylated DNA affects Cas9 binding and prevents target
cleavage
Next, we investigated if DNA modifications can prevent
DNA targeting by type II-A Cas9 in vitro (Figure 4A).
The ability of Cas9 to degrade unmodified, 5-hmC and 5-
ghmC targets was assessed by incubation of a reconstituted
Cas9–sgRNA-loaded complex with target DNAs. As for
Cascade/Cas3, Cas9–sgRNA complexes were able to cleave
the 5-hmCDNA and the unmodified control DNA, but not
the 5-ghmC DNA (Figure 4B). To determine the molec-
ular basis for inhibition of 5-ghmC DNA cleavage, EM-
SAs were conducted using a catalytically inactive version of
Cas9 (dCas9) (Figure 4C). Surprisingly, the assays showed
that the sequence-specific binding of 5-hmC target DNA
is consistently increased compared to binding of unmod-
ified DNA targets. In contrast, the binding affinity of 5-
ghmC target DNA is consistently decreased compared to
targets with unmodified DNA. Combined, these results in-
dicate that 5-ghmC partially affects type II-A interference
by lowering the binding affinity of Cas9–sgRNA complexes
to the target DNA. Additionally, glucosylation may affect
the ability of Cas9 to restrict target DNA by protecting the
scissile bonds from the catalytic residues, rendering Cas9–
sgRNA complex-mediated interference even less effective.
Glucosyl-5-hydroxymethylation of the PAM does not abolish
cleavage by Cas9
We next investigated whether glucosyl-5-hydroxymethylat
ion of cytosines in the PAM region is sufficient to inhibit
DNA cleavage by Cas9. Interactions between the target
DNA and Cas9 are initiated at the PAM by two arginines
probing the major groove for the two guanines in the 5′-
NGG-3′ PAM (48). Upon PAM recognition, Cas9 sequen-
tially unwinds the protospacer dsDNA and forms an R-
loop structure between the targetDNAstrand and the guide
RNA. Based on their location in the major groove of the
DNA,we hypothesized that glucosyl-5-hydroxymethylation
of the two cytosines (3′-NCC-5′) complementary to the
guanines of the PAM could inhibit the PAM recognition
process, and could abolish target cleavage. We utilized tar-
get DNA containing 5-hmC or 5-ghmC modifications ei-
ther proximal to the protospacer (3′-NhmCC-5′), distal to
the protospacer (3′-NChmC) or at both cytosine residues
in the PAM-complementary region (3′-NhmChmC-5′). We
found that Cas9-mediated cleavage of target DNA con-
taining 5-hmC or 5-ghmC opposite the guanines in the
5′-NGG-3′ PAM was not inhibited by such modifications.
Thus, cytosine glucosylating modifications of the PAM-
complementary sequence are not sufficient and do not con-
tribute to escape from Cas9-mediated interference (Figure
5).
DNA cleavage by Cas12a is not inhibited by glucosyl-5-
hydroxymethylation
To investigate the activity of type V-A Cas12a systems to
cleave glucosylated DNA, we performed DNA cleavage as-
says using Cas12a from Francisella novicida (FnCas12a;
Figure 6A). Strikingly, DNA cleavage assays with Cas12a-
crRNA complex and various DNA targets reveal Cas12a
activity is not affected by 5-hmC or 5-ghmC modifications
of the target (Figure 6B). Furthermore, EMSAs with cat-
alytically inactive Cas12a containing mutations E1006A
and R1218A (dCas12a) (42) shows similar binding affini-
ties for unmodified, 5-hmC, and 5-ghmC target DNA (Fig-
ure 6C). These results indicate that DNA targeting by
Cas12a–crRNA complexes, in contrast to Cascade and
Cas9–crRNA effector complexes, is not inhibited by 5-hmC
or 5-ghmC modifications in the DNA.
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Figure 6. Effect of T4 DNA modifications on type V-A CRISPR–Cas sgRNA mediated DNA targeting. (A) Schematic of DNA targeting by Cas12a.
Modified cytosine residues are indicated in red. Cleavage sites are indicated by black arrows. (B) Cleavage assay of Cas12a on 98 bp modified targets
(indicated by black arrow). Cas12a is loaded with either targeting crRNA (C crRNA) or non-targeting crRNA (NC crRNA). Cleavage products of Cas12a
are 49 and 44 bp. The marker is indicated by white arrows. (C) Electrophoretic Mobility Shift Assay (EMSA) of Cas12a on target DNA containing C,
5-hmC or 5-ghmC (indicated by black arrow) at increasing protein concentrations [nM]. Fraction of bound target is indicated by white arrows.
Structural modelling of modified target DNA into crRNA–
effector complexes
In order to further understand the contrasting effects of
DNA glucosylation on CRISPR–Cas effector complexes
we analyzed potential steric clashes of DNA modifica-
tions in the target and non-target strand of the DNA at
each nucleotide position by statically modelling glucosyl-5-
hydroxymethyl modifiedDNA in existing structural models
of ternary effector complexes (E. coli Cascade (PDB: 5H9F
(40)), SpCas9 (PDB: 5F9R (41)) and FnCas12a (PDB:
5NFV (42))). As structures of 5-ghmC are not available, we
used the structure of a 5-ghmT (PDB: 308D), in which the
glucosyl-hydroxymethyl modification is also positioned on
carbon 5 of the base. Static modelling does not take into
account potential flexibility of polypeptide and nucleic acid
chains, but allows for the identification of potential clashes
and thereby could provide an idea about how effector com-
plexes might accommodate modified DNA substrates.
In both the Cascade and Cas9 models, multiple clashes
are observed between the polypeptide chain and 5-ghmC
modifications of nucleotides in both target DNA strands
(Figure 7A and B, Supplementary Table S6). Clashes with
Cascade are observed for 17 out of 32 target strand nu-
cleotides (TS, complementary to the crRNA) and for 3 out
of 7 of the non-target strand (NTS) nucleotides of which
the position is identified. Clashes with Cas9 are observed
for 3 out of 20 TS nucleotides and for 5 out of 9 of the NTS
nucleotides that are structurally defined in the crystal struc-
ture of Cas9. Several of the modifications in both Cascade
and Cas9 that cause steric clashes are located in the segment
of the DNA that base-pairs with the crRNA seed sequence.
Because interactions with the seed sequence are essential for
R-loop formation and efficient targeting by both Cascade
and Cas9 (46), such clashes can explain why DNA target-
ing by Cascade and Cas9 is inhibited by 5-ghmC modifica-
tions of the target DNA. In contrast, such clashes are not
observed in the Cas12a model, in which 5-ghmC modifica-
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Figure 7. Potential steric clashes between target nucleotide 5-ghmC modifications and CRISPR effector proteins. (A) Multiple clashes (indicated in red)
are observed between the polypeptide chains of Cascade and 5-ghmCmodifications of nucleotides in the target strand (TS, complementary to the crRNA)
and non-target strand (NTS). (B) Clashes are mostly observed between the polypeptide chains of Cas9 and 5-ghmC modifications of nucleotides in the
seed region. (C) No clashes are observed in the seed region for Cas12a.
tions can be accommodated at almost all positions within
the crRNA-target DNA heteroduplex (Figure 7C).
It should be noted that for both Cas9 andCas12a, clashes
between the 5-ghmC modifications and the polypeptide
chain are observed when 5-ghmC modifications are mod-
elled onto the PAM nucleobases (Figure 7B and C). How-
ever, specifically these PAMs cannot contain cytosines at
these positions (Figure 7) since Cas9 and Cas12a recog-
nize 5′-NGG-3′ and 5′-(T)TTN-3′ PAMs, respectively. In
line with our biochemical experiments with Cas9 (Figure 5),
modifications of the cytosine nucleotides opposite to the 5′-
NGG-3′ PAM do not appear to introduce clashes with the
polypeptide chain of Cas9 in our models. In both models,
additional clashes can be found upstream the protospacer-
PAM segment, and within the PAM-distal protospacer re-
gion. Because these segments of the DNA are generally not
essential for efficient DNA targeting (Cas9: (49)/Cas12a:
(42,50,51)), we hypothesize that the potential clashes be-
tween 5-ghmC modifications and the polypeptide chain in
our models will have a limited effect on DNA targeting. In
summary, we conclude that 5-ghmC modifications in the
target DNA are likely to result in clashes with Cascade
and Cas9 and impair their DNA binding activity. However,
Cas12a appears to be able to accommodate modified nu-
cleobases due to a much more open structure. These mod-
els corroborate our experiments that demonstrate Cascade
and Cas9 activity, but not Cas12a activity, is inhibited by
5-ghmC modification of target DNA.
DISCUSSION
Phages have evolved diverse systems that allow them to
counteract bacterial defense mechanisms. Evasion from
CRISPR–Cas defense can occur by mutation of the pro-
tospacer or PAM sequence (14–16), target site deletion
(52), genome recombination (19), or by production of anti-
CRISPR proteins (23,25,26). Here, we show how chemical
modifications of DNA nucleotides can render phages resis-
tant to interference by specific CRISPR–Cas types. Our re-
sults demonstrate that CRISPR–Cas type I-E and type II-A
interference is severely impaired by glucosyl modification of
the cytosine bases (5-ghmC) in T4 phage DNA. However,
the type V-A effector protein Cas12a remains able to bind
and cleave T4 DNA even if it is glucosylated, suggesting the
possibility that type V systems have evolved to combat co-
valently modified phages.
Phage encoded DNA modifications are well known
antagonists of microbial defense systems, most notably
restriction–modification systems (53). Apart from the
known inhibitory effect ofDNAmodifications onR–Msys-
tems, the effect on CRISPR–Cas systems has been studied
for some DNA modifications. Small modifications such as
N6-methylation of adenine in 5′-GATC-3′ sequences do not
prevent interference by the type II-A CRISPR–Cas system
in Streptococcus thermophilus (54). Later, Yaung and col-
leagues showed that DNA modifications of T4 phages do
not protect the phage from Cas9 interference (55). By con-
trast and in line with our results, Bryson and colleagues
showed that Cas9 interference can be inhibited by glucosy-
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lation of DNA when using the naturally occurring combi-
nation of crRNA and trans-activating crRNA (tracRNA),
and to a lower extent using the engineered single guideRNA
(sgRNA) (56). Also, the degree of inhibition is strongly de-
pendent on the selected targetDNA sequence, and therefore
the positions of base modifications. While this manuscript
was in preparation, Strotskaya and colleagues showed that
no interference nor CRISPR array expansion was observed
when T4 was targeted by the type I-E system in E. coli
(57).The insensitivity of T4 to CRISPR interference was at-
tributed to either DNA modifications or to yet unknown
phage mechanisms. Here we demonstrate that the insensi-
tivity is a result of DNA modification.
The inability of Cascade and Cas9 to bind and cleave 5-
ghmC DNA is likely due to steric clashes between the glu-
cose modifications of the protospacer segment of the tar-
get DNA and the polypeptide chain of the effector com-
plexes. Our results show that Cas9 can still read the PAM
nucleotides if only the PAM-complementary cytosines are
glucosylated, which is in agreement with structural model-
ing. The inability of Cas9 to cleave fully glucosylated targets
suggests that after successful PAM recognition, subsequent
recognition of the protospacer is hampered.
The effect of DNA modifications on CRISPR–Cas in-
terference is most likely dependent on the target DNA se-
quence and thereby the degree of DNA modifications. Al-
though Cas9 and Cas12a target roughly the same region of
our tested target DNA, the chosen target sites are differ-
ent and result in different degrees of DNA modifications
in the seed regions of the protospacer (12,58,59). However,
our structural modeling suggests that Cas12a has an intrin-
sically more open architecture and we predict that it can ac-
commodate and better deal with bulky DNAmodifications
regardless of their position in the protospacer.
In addition to steric hindrance effects, changes in chemi-
cal presentation of nucleobases can result in decreased bind-
ing affinities. Changes in the chemical signature of themajor
and minor groove by replacement of guanines in the PAM
with purine analogs is shown to attenuate binding affini-
ties of the type I-F Csy complex in Pseudomonas aeruginosa
(60). Similarly, glucosylation of DNA is known to change
the chemical signature and stability of theDNAduplex.Hy-
drogen bonds can be formed between the side groups of the
glucosyl moieties and neighboring bases (61). These inter-
actions alter the roll, slide, and twist angles of base pairs (62)
which could impair R-loop formation and thereby prevent
cleavage of the modified targets.
While phage T4 contains 70% -glucosylated and 30% -
glucosylated DNA, this study only examined the effect of
-glucosyl linkages in vitro (33). The effect of -glucosyl-5-
hydroxymethylation on CRISPR–Cas interference remains
to be determined. Nevertheless, based on a comparable oc-
cupation of the major groove by -5-ghmC, we expect there
to be little or no differences between the effects of - or -
coupled glucosyls on CRISPR interference.
Our finding that DNA containing glucosyl-5-
hydroxymethylated cytosine bases can be cleaved by a
CRISPR–Cas type V-A system, but inhibits binding by
crRNA–effector complexes from type I-E and II-A sys-
tems, has important implications that could be exploited
for genome engineering applications (63). Firstly, Cas9
is not inhibited by 5-hmC modifications which allows
editing of cells with 5-hmC modified regions such as
some neuronal cells (64,65). Secondly, the inhibitory effect
of 5-ghmC on Cas9 targeting could be used to introduce
non-cleavable DNA templates for homology directed repair
(HDR) applications. Lastly, the seemingly robust activity
of Cas12a could be harnessed for genome engineering of
organisms and bacteriophages that contain hypermodified
bases such as the pathogen Trypanosoma brucei (66) and
phage T4.
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